<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025063</url>
  </required_header>
  <id_info>
    <org_study_id>CBPD952AUS18T</org_study_id>
    <nct_id>NCT01025063</nct_id>
  </id_info>
  <brief_title>Use of Spectral OCT in Combination Therapy</brief_title>
  <acronym>Spectral OCT</acronym>
  <official_title>Use of Spectral OCT in Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnes Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barnes Retina Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and efficacy of treatment of choroidal&#xD;
      neovascularization (CNV) due to age-related macular degeneration (AMD) with a combination of&#xD;
      ranibizumab (Lucentis) and verteporfin PDT (Visudyne), as compared with ranibizumab&#xD;
      monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>This pilot study observed anatomical measures which are currently not defined since the new technology is unclear in regards to what changes are seen at the level of the RPE and photoreceptors.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Lucentis (PRN group)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis (3 Injections over three months)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>PDT (Reduced Fluence) and Lucentis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Barnes Retina Institute clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Patients with visual acuity of 20/40-20/320 in the study eye&#xD;
&#xD;
          -  Subfoveal choroidal neovascularization (CNV) must be at least 50% of the total lesion&#xD;
             size.&#xD;
&#xD;
          -  Total area of lesion components other that CNV must be less than 50% of the total&#xD;
             lesion size.&#xD;
&#xD;
          -  The lesion must be &lt; 5400microns in greatest linear dimension (GLD).&#xD;
&#xD;
          -  Lesion size &lt; 10 DA&#xD;
&#xD;
          -  Occult with no classic CNV lesions must have presumed recent disease progression:&#xD;
&#xD;
               1. Blood associated with the lesion at baseline&#xD;
&#xD;
               2. Loss of visual acuity in the previous 3 months: a: &gt; 5 letter loss (ETDRS&#xD;
                  equivalent) or b: 2 or more lines using a snellen or equivalent chart&#xD;
&#xD;
               3. &gt; 10% increase in GLD as assessed by fluorescein angiography in the previous 3&#xD;
                  months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of angioid streaks, presumed ocular histoplasmosis syndrome, pathologic&#xD;
             myopia (-8 or more with evidence of posterior segment abnormalities consistent with&#xD;
             pathologic myopia), or CNV secondary to causes other than AMD&#xD;
&#xD;
          -  Geographic atrophy in the study eye&#xD;
&#xD;
          -  Tear (rip) of the retinal pigment epithelium&#xD;
&#xD;
          -  Presence of fibrosis, hemorrhage, pigment epithelial detachments, or other&#xD;
             hypofluorescent lesions obscuring greater than 50% of the CNV lesion&#xD;
&#xD;
          -  Intraocular surgery within 6 weeks of enrollment&#xD;
&#xD;
          -  Active or history of ocular inflammation or infection in the study eye within the last&#xD;
             30 days&#xD;
&#xD;
          -  Subretinal hemorrhage &gt; 50% of the total lesion&#xD;
&#xD;
          -  History of submacular surgery, or transpupillary thermotherapy in the study eye&#xD;
&#xD;
          -  Patients with intraocular pressure greater than 30 mm/Hg on 2 pressure-lowering&#xD;
             medications&#xD;
&#xD;
          -  Patients with severe disciform scarring&#xD;
&#xD;
          -  History of intraocular surgery in the study eye including pars plana vitrectomy,&#xD;
             except for uncomplicated cataract surgery within 60 days prior to screening&#xD;
&#xD;
          -  History of YAG laser posterior capsulotomy in the study eye within 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Inability to make study visits&#xD;
&#xD;
          -  Advanced glaucoma, uncontrolled glaucoma in the study eye (defined as intraocular&#xD;
             pressure, IOP ≥ 25 mmHg) despite treatment with two or more topical pharmacological&#xD;
             anti-glaucomatous medication)&#xD;
&#xD;
          -  Allergies to porphyrins or a known hypersensitivity to any component of Visudyne®&#xD;
&#xD;
          -  Patients with porphyria&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barnes Retina Institute</investigator_affiliation>
    <investigator_full_name>Rhonda Weeks</investigator_full_name>
    <investigator_title>Gaurav K. Shah, MD</investigator_title>
  </responsible_party>
  <keyword>Spectral OCT</keyword>
  <keyword>Choroidal Neovascularization</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Visudyne</keyword>
  <keyword>PDT</keyword>
  <keyword>anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

